Please assess the completion status of the following clinical trial:

Trial Title: Tizanidine and Pain After Herniorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist's physiologic state I-III patients undergoing unilateral inguinal herniorrhaphy~Exclusion Criteria:~* chronic pain~* bleeding disorders~* renal or hepatic insufficiency~* patients on chronic non-steroidal anti-inflammatory medications~* recurrent hernias~* emergency cases

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tizanidine (Type: EXPERIMENTAL): Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
- Placebo (Type: PLACEBO_COMPARATOR): Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).